{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:23:11Z","timestamp":1755220991064,"version":"3.43.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"DOI":"10.7759\/cureus.89590","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:00:02Z","timestamp":1754632802000},"source":"Crossref","is-referenced-by-count":0,"title":["Adverse Reactions to Taxanes in Premedicated Cancer Patients: A Prospective Observational Study"],"prefix":"10.7759","author":[{"given":"M. B","family":"Febina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy  L","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keechilat","family":"Pavithran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh  K","family":"D.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1039\/d3np00017f","article-title":"From plant to cancer drug: lessons learned from the discovery of taxol","volume":"40","author":"Cech NB","year":"2023","unstructured":"Cech NB, Oberlies NH. From plant to cancer drug: lessons learned from the discovery of taxol. Nat Prod Rep. 2023, 40:1153-7. 10.1039\/d3np00017f","journal-title":"Nat Prod Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao LR","year":"2022","unstructured":"Tsao LR, Young FD, Otani IM, Castells MC. Hypersensitivity reactions to platinum agents and taxanes. Clin Rev Allergy Immunol. 2022, 62:432-48. 10.1007\/s12016-021-08877-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2024.16.2.142","article-title":"Hypersensitivity reactions to taxanes: a multicenter study for outcomes and safety of rapid drug desensitization","volume":"16","author":"Durmaz MSB","year":"2024","unstructured":"Durmaz MSB, Unutmaz DG, Demir M, Goksel O, Dursun AB, Bavbek S. Hypersensitivity reactions to taxanes: a multicenter study for outcomes and safety of rapid drug desensitization. Allergy Asthma Immunol Res. 2024, 16:142-53. 10.4168\/aair.2024.16.2.142","journal-title":"Allergy Asthma Immunol Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13960","article-title":"Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer","volume":"26","author":"Barroso-Sousa R","year":"2021","unstructured":"Barroso-Sousa R, Vaz-Luis I, Di Meglio A, et al.. Prospective study testing a simplified paclitaxel premedication regimen in patients with early breast cancer. Oncologist. 2021, 26:927-33. 10.1002\/onco.13960","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-03402-5","article-title":"Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel","volume":"316","author":"Trager MH","year":"2024","unstructured":"Trager MH, Kuo AM, Dusza SW, et al.. Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel. Arch Dermatol Res. 2024, 316:665. 10.1007\/s00403-024-03402-5","journal-title":"Arch Dermatol Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2021.12.8.4","article-title":"Premedications for cancer therapies: a primer for the hematology\/oncology provider","volume":"12","author":"Clemmons A","year":"2021","unstructured":"Clemmons A, Gandhi A, Clarke A, Jimenez S, Le T, Ajebo G. Premedications for cancer therapies: a primer for the hematology\/oncology provider. J Adv Pract Oncol. 2021, 12:810-32. 10.6004\/jadpro.2021.12.8.4","journal-title":"J Adv Pract Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.12.4333","article-title":"Efficacy of omitting H\u2082 antagonists versus famotidine in taxane hypersensitivity reactions prophylaxis: a randomized, prospective, open-label, controlled trial","volume":"25","author":"Chantharakhit C","year":"2024","unstructured":"Chantharakhit C, Ruchakorn T, Theeratrakul P, Pengnoraphat B. Efficacy of omitting H\u2082 antagonists versus famotidine in taxane hypersensitivity reactions prophylaxis: a randomized, prospective, open-label, controlled trial. Asian Pac J Cancer Prev. 2024, 25:4333-8. 10.31557\/APJCP.2024.25.12.4333","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5049.115608","article-title":"Clinical causality assessment for adverse drug reactions","volume":"57","author":"Parida S","year":"2013","unstructured":"Parida S. Clinical causality assessment for adverse drug reactions. Indian J Anaesth. 2013, 57:325-6. 10.4103\/0019-5049.115608","journal-title":"Indian J Anaesth"},{"key":"ref9","article-title":"Incidence of hypersensitivity reactions from paclitaxel","volume":"101","author":"Tangsaghasaksri R","year":"2018","unstructured":"Tangsaghasaksri R , Jainan P. Incidence of hypersensitivity reactions from paclitaxel. J Med Assoc Thai. 2018, 101:150-4.","journal-title":"J Med Assoc Thai"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4821","article-title":"Exclusion of ranitidine from premedication regimens during paclitaxel treatment","volume":"10","author":"Huntjens DW","year":"2024","unstructured":"Huntjens DW, Vanhommerig JW, van de Veen W, Crul M. Exclusion of ranitidine from premedication regimens during paclitaxel treatment. JAMA Oncol. 2024, 10:131-2. 10.1001\/jamaoncol.2023.4821","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241269766","article-title":"Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy","author":"Villarreal-Gonz\u00e1lez RV","year":"2024","unstructured":"Villarreal-Gonz\u00e1lez RV, Vidal-Guti\u00e9rrez O, Mart\u00ednez-Moyano JA, et al.. Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy. J Oncol Pharm Pract. 2024, 10781552241269766. 10.1177\/10781552241269766","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.940239","article-title":"A systemic review of taxanes and their side effects in metastatic breast cancer","volume":"12","author":"Lai JI","year":"2022","unstructured":"Lai JI, Chao TC, Liu CY, Huang CC, Tseng LM. A systemic review of taxanes and their side effects in metastatic breast cancer. Front Oncol. 2022, 12:940239. 10.3389\/fonc.2022.940239","journal-title":"Front Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines","volume":"28","author":"Rosell\u00f3 S","year":"2017","unstructured":"Rosell\u00f3 S, Blasco I, Garc\u00eda Fabregat L, Cervantes A, Jordan K. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2017, 28:iv100-18. 10.1093\/annonc\/mdx216","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15010002","article-title":"Personalized risk assessment for taxane-induced hypersensitivity reactions: a systematic review and meta-analysis","volume":"15","author":"Park HJ","year":"2024","unstructured":"Park HJ, Ko M, Kim IW, Oh JM. Personalized risk assessment for taxane-induced hypersensitivity reactions: a systematic review and meta-analysis. J Pers Med. 2024, 15:10.3390\/jpm15010002","journal-title":"J Pers Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00318","article-title":"Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction on the basis of real-world data: PAC-HSR score","volume":"10","author":"Sa-Nguansai S","year":"2024","unstructured":"Sa-Nguansai S, Sukphinetkul R. Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction on the basis of real-world data: PAC-HSR score. JCO Glob Oncol. 2024, 10:e2400318. 10.1200\/GO-24-00318","journal-title":"JCO Glob Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2343852","article-title":"Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy","volume":"17","author":"Xiao D","year":"2024","unstructured":"Xiao D, Yang Z, Shi Y, Yang W, Zhang Y. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy. Expert Rev Clin Pharmacol. 2024, 17:525-32. 10.1080\/17512433.2024.2343852","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud V","year":"2016","unstructured":"Sibaud V, Leb\u0153uf NR, Roche H, et al.. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016, 26:427-43. 10.1684\/ejd.2016.2833","journal-title":"Eur J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali HI","year":"2022","unstructured":"Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022, 155:131-66. 10.1016\/bs.acr.2022.02.007","journal-title":"Adv Cancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28040273","article-title":"Chemotherapy-induced neuropathy and diabetes: a scoping review","volume":"28","author":"Sempere-Bigorra M","year":"2021","unstructured":"Sempere-Bigorra M, Juli\u00e1n-Rochina I, Cauli O. Chemotherapy-induced neuropathy and diabetes: a scoping review. Curr Oncol. 2021, 28:3124-38. 10.3390\/curroncol28040273","journal-title":"Curr Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18203\/2319-2003.ijbcp20223350","article-title":"Taxanes-induced hypersensitivity reactions in cancer chemotherapy patients reported at an adverse drug reaction monitoring centre at a tertiary care hospital","volume":"12","author":"Begum SH","year":"2022","unstructured":"Begum SH, VR M, Sahayaraj C, et al.. Taxanes-induced hypersensitivity reactions in cancer chemotherapy patients reported at an adverse drug reaction monitoring centre at a tertiary care hospital. Int J Basic Clin Pharmacol. 2022, 12:29. 10.18203\/2319-2003.ijbcp20223350","journal-title":"Int J Basic Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398511-adverse-reactions-to-taxanes-in-premedicated-cancer-patients-a-prospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T06:00:03Z","timestamp":1754632803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398511-adverse-reactions-to-taxanes-in-premedicated-cancer-patients-a-prospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.89590","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}